Interstitial Lung Disease News

Increasing wildfire incidence, along with greater overall air pollution, may be contributing to risks for rheumatoid arthritis and RA-associated interstitial lung disease, according to findings published in Arthritis & Rheumatology.

Jobs with high IPF mortality ratios differed by sex, but notable categories for both included the public administration industry and health care practitioners and technical occupations, according to study findings.

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, according to a press release.

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with rheumatoid arthritis-associated interstitial lung disease, according to data published in The Lancet Rheumatology.

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new online educational resource.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Patients with rheumatoid arthritis who demonstrate consistent long-term elevation of inflammatory markers have an increased risk for interstitial lung disease, according to data published in Arthritis Research & Therapy.